

DNA Damage Response Inhibitors (DDRi) Phase 2 study: tuvusertib—epithelial ovarian cancer




Tuvusertib and lartesertib are investigational and not approved for use. Niraparib in combination with tuvusertib is not approved for use. The safety and efficacy of this combination in EOC has not been established. There is no guarantee tuvusertib and lartesertib will be approved in any indication by any health authority worldwide.

Sponsor: Affiliates of Merck KGaA, Darmstadt, Germany

(NCT06433219) [Recruiting]

DDRiver EOC 302: Phase 2, randomized, open-label, multicenter study



^aIncludes ovarian, primary peritoneal, and/or fallopian tube cancer that is recurrent. ^bBy local standard-of-care tests. ^cClinically benefitted from PARPi maintenance prior to documented progression (defined by ≥6 months of treatment duration with no progressive disease); documentation of disease progression must be within 28 days of last PARPi dose taken. 1LM participants were allowed one additional platinum course between progression and study entry (only 1 line of PARPi maintenance is allowed with or without bevacizumab); 2LM participants were not allowed any additional treatment before study entry.

^dPer RECIST 1.1 (as assessed by investigator).

1LM, first line maintenance; 2LM, second line maintenance; AE, adverse event; BRCA, BRCA1/2 gene; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EOC, epithelial ovarian cancer; Est. estimated; HRD; homologous recombination deficiency; OR, objective response; PARPi, poly (ADP-ribose) polymerase inhibitors; PD, pharmacodynamics; PFS, progression-free survival; PK, pharmacokinetics; RECIST, Response Evaluation Criteria in Solid Tumors; TFIp, treatment-free interval on platinum rechallenge.

1. Kristeleit R, et al. *Int J Gynecol Cancer*. 2025;35(2):101597.

This information is current as of March 2025. ©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. This material is intended for healthcare professionals only.



For more information on this clinical trial, scan the QR code.

